Aptuit, LLC has relocated its recently acquired subsidiary Kuecept to its Oxford UK site, and added further formulation and safety assessment capacity for IND de-risking and enabling packages.
 
Kuecept provides phase appropriate pre-formulation testing, preclinical dose-vehicle screening and formulation development. Kuecept has expertise in respiratory, parenteral and oral formulation development and offers formulation rescue consultancy for moving challenging APIs through IND/CTA enabling safety assessment.
 
Aptuit chief executive officer Dr. Jonathan Goldman said, “We have invested over $2.5 million in the last six months in our formulation development services both in Verona and Oxford. This continued investment allows us to offer seamless integrated solutions in Drug Discovery, CMC and Preclinical Biosciences. The new laboratories, equipment and people have significantly increased our capacity and expertise in this early development space. We have also focused on improving our ability to handle high potency compounds.”